Nutra Pharma is announcing their newest product, Luxury Feet; is now available for purchase on Amazon.com Plantation, Florida, April 15, 2021 -- -- Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, announced today that their newest product, Luxury...
NEWSROOM
Pet Pain Away
Nutra Pharma Announces Distribution of Luxury Feet for the Relief of Pain from High Heels
Nutra Pharma is announcing the marketing and distribution plans for Luxury Feet; an over-the-counter pain reliever for women who experience pain or discomfort due to high heels and stilettos Plantation, Florida, March 16, 2021 -- -- Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human...
Nutra Pharma Engages Quality and Regulatory Professionals Ahead of Clinical Trials
Nutra Pharma is providing updates on their work in improving capabilities and certifications in their laboratory for drug production and validation in preparation of expanded OTC sales and clinical trials Plantation, Florida, March 11, 2021 -- -- Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple...
Nutra Pharma Provides Updates on Laboratory Upgrades and Certifications
Nutra Pharma is providing updates on their work in improving capabilities and certifications in their laboratory for drug production and validation Plantation, Florida, February 23, 2021 -- -- Nutra Pharma Corporation (OTC PINK: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain,...
Nutra Pharma Announces New Intellectual Property Update and Engages Additional Intellectual Property Attorneys
Plantation, Florida, February 12, 2021 -- -- Nutra Pharma Corporation (OTC PINK: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, announced today that they are focusing on their intellectual property portfolio and have engaged their IP attorneys at Christopher & Weisberg P.A....
Nutra Pharma Letter to Shareholders
Plantation, Florida, January 12, 2021 -- -- Nutra Pharma Corporation (OTC PINK: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, announced today that the Company's Chief Executive Officer, Rik J Deitsch, has published a Letter to Shareholders on the Company's website. “The last year was...